← Leaderboards
Sang-Moo Kang
Emory University
$13,182,056
Attributed
$13,482,055
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,482,055 · 10
By mechanism
R01$10,665,451 · 3
R21$1,298,146 · 3
R43$599,998 · 1
R41$497,223 · 2
R56$421,237 · 1
Top collaborators
- Fu Shi Quan2 shared
Most similar at Emory University
Same institution · by research overlap
- Jan-Michael Axel Klapproth$781,334
- Veronika I Zarnitsyna$1,729,837
- Larry J Anderson$1,008,400
- Canhua Xiao$6,855,838
- Lisa C Flowers$4,132,008
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusInfluenzaVaccinesInfluenza Virus VaccineFerretsImmunityVaccine CandidateAnimal ModelVaccinationVirus-Like ParticleBaseProtective EfficacyMouse ModelTandem Repeat SequencesImmunogenicityAntibodiesInfluenzavirusRecombinantsHemagglutininEpitopesInfluenza A Virus, H1n1 SubtypeAdjuvantSeasonal InfluenzaImmune Response
Grant awards (32)
Seasonal and universal Vaccination in aged populations with pre-existing immunity$542,726
R01 · FY2025 · AI · contact PI
Seasonal and universal Vaccination in aged populations with pre-existing immunity$542,726
R01 · FY2024 · AI · contact PI
Seasonal and universal Vaccination in aged populations with pre-existing immunity$542,726
R01 · FY2023 · AI · contact PI
Seasonal and universal Vaccination in aged populations with pre-existing immunity$542,726
R01 · FY2022 · AI · contact PI
Seasonal and universal Vaccination in aged populations with pre-existing immunity$501,999
R01 · FY2021 · AI · contact PI
Universal epitopes-based recombinant influenza vaccines$233,688
R21 · FY2021 · AI · contact PI
Influenza vaccines inducing broadly cross protective immunity$501,250
R01 · FY2020 · AI · contact PI
Multi NA-based influenza vaccines$272,223
R41 · FY2020 · AI · contact PI
Universal epitopes-based recombinant influenza vaccines$193,854
R21 · FY2020 · AI · contact PI
Influenza vaccines inducing broadly cross protective immunity$501,250
R01 · FY2019 · AI · contact PI
Influenza vaccines inducing broadly cross protective immunity$717,148
R01 · FY2018 · AI · contact PI
New RSV Vaccines with Improved Safety and Efficacy$225,000
R41 · FY2018 · AI · contact PI
VLP Vaccine Technology$726,333
R01 · FY2017 · AI · contact PI
Influenza vaccines inducing broadly cross protective immunity$446,710
R01 · FY2017 · AI · contact PI
VLP Vaccine Technology$726,333
R01 · FY2016 · AI · contact PI
LAIV Inducing Cross Protection$227,000
R21 · FY2016 · AI · contact PI
VLP Vaccine Technology$726,333
R01 · FY2015 · AI · contact PI
Influenza vaccines inducing broadly cross protective immunity$413,221
R01 · FY2015 · AI · contact PI
LAIV Inducing Cross Protection$187,604
R21 · FY2015 · AI · contact PI
VLP Vaccine Technology$726,333
R01 · FY2014 · AI · contact PI
Influenza vaccines inducing broadly cross protective immunity$413,221
R01 · FY2014 · AI · contact PI
VLP Vaccine Technology$838,288
R01 · FY2013 · AI · contact PI
Influenza vaccines inducing broadly cross protective immunity$388,428
R01 · FY2013 · AI · contact PI
Influenza vaccines inducing broadly cross protective immunity$413,221
R01 · FY2012 · AI · contact PI
Influenza vaccines inducing broadly cross protective immunity$438,366
R01 · FY2011 · AI · contact PI
Novel nanotechnology based oral influenza vaccines$417,740
R56 · FY2011 · AI · contact PI
Influenza vaccines inducing broadly cross protective immunity$16,113
R01 · FY2011 · AI · contact PI
Novel nanotechnology based oral influenza vaccines$3,497
R56 · FY2011 · AI · contact PI
Adjuvant-containing chimeric virus-like particles as improved influenza vaccines$299,999
R43 · FY2010 · AI
Adjuvant-containing chimeric virus-like particles as improved influenza vaccines$299,999
R43 · FY2009 · AI
Enhancement of targeting HIV vaccine to dendritic cell$228,000
R21 · FY2004 · AI
Enhancement of targeting HIV vaccine to dendritic cell$228,000
R21 · FY2003 · AI